Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info

Pfizer execs to stand trial for cover-up of drug trial results

Monday, April 02, 2012 by: Ethan A. Huff, staff writer
Tags: Pfizer, executives, cover-up

Most Viewed Articles
Popular on Facebook
(NaturalNews) Four former executives at Pfizer Inc., the world's largest drug company. -- Henry McKinnell, John LaMattina, Karen Katen, Joseph Feczko -- as well as Gail Cawkwell, Pfizer's current Vice President of Medical Affairs, will all face trial for allegedly concealing the unfavorable results of drug trials involving Celebrex and Bextra. Courthouse News Service (CNS) reports that U.S. District Judge Laura Taylor Swain has denied requests made by defendants to dismiss the case, which means all five individuals will be held to account for their actions.

The securities class-action lawsuit, which was filed by the Teachers Retirement System of Louisiana (TRSL) on behalf of Pfizer stockholders, alleges that the five defendants violated federal securities laws by concealing the results of studies involving Celebrex, a COX-2 inhibiting anti-inflammatory drug, and Bextra, a non-steroidal anti-inflammatory drug (NSAID) that was pulled from the market in 2005.

According to the suit, the five defendants made misleading statements in their public filings about the drug trials, and also omitted important information that exposed both Celebrex and Bextra as being dangerous. And despite numerous attempts by Pfizer and the defendants to have the case dismissed or reconsidered, the case will now proceed as intended following Judge Swain's ruling that the plaintiffs provide sufficient evidence to show that Celebrex and Bextra are "linked to adverse cardiovascular events to a statistically significant degree, and that these results were known to Defendants."

Because of its class-action status, the lawsuit will also potentially address a number of other lawsuits against Pfizer as well, since it has now been revealed that Celebrex, which is still on the market, has been known to cause heart problems since at least as early as 2004. If the plaintiffs are successful in winning their case, Pfizer shareholders who purchased stock between October 31, 2000, and October 19, 2005, will be covered.

"Over the past seven years, this court has become familiar with both the parties to and the subject matter of this action, and so believes that concentrating this litigation in this forum would promote judicial economy," wrote Judge Swain in her ruling.

Just prior to the ruling, Pfizer actually ended a post-approval safety study of Celebrex due to difficulty finding patients willing to enroll in it. Though the company was initially required by the U.S. Food and Drug Administration (FDA) to conduct such a study, the regulatory agency ended up deciding to simply let Pfizer off the hook rather than hold it accountable to these requirements (http://www.cbsnews.com).

Sources for this article include:




STAY INFORMED! Free subscription to the Health Ranger's email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.